Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Dendermonde – page 2

2 119 clinical trials in Dendermonde, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Dendermonde at a glance
2 119
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 119 trials in Dendermonde

Open in trial search

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Narcolepsy

Recruiting

Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Narcolepsy

Recruiting

Phase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Vitiligo

Recruiting

Efficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY4005130
  • Sponsor:Eli Lilly & Co.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim Espana S.A.

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

A study to evaluate the effectiveness and safety of pridopidine hydrochloride in patients with amyotrophic lateral sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

Obesity+1

Recruiting

A study to evaluate the effectiveness and safety of eloralintide in adults with obesity or overweight without type 2 diabetes.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Dendermonde

What the registry says about research in the country

01 Cardiovascular Disease Prevention

Innovative research focusing on lipoprotein reduction and prevention of major cardiovascular events in patients with established CVD. Studies evaluating new therapeutic approaches for reducing cardiovascular risks.

  • Atherosclerotic cardiovascular disease prevention
  • Lipid management therapies
  • Cardiovascular risk reduction

Cutting-edge trials examining novel compounds for improving cardiovascular outcomes.

02 Cardiac Rhythm Disorders

Studies investigating treatments for atrial fibrillation and stroke prevention. Research comparing new anticoagulation therapies with established treatments for preventing systemic embolism.

  • Stroke prevention in AF
  • Novel anticoagulants
  • Cardioembolic event prevention

Advanced clinical research focusing on improving outcomes in cardiac rhythm management.

03 Specialized Cardiac Conditions

Research targeting rare cardiac conditions including transthyretin amyloidosis with cardiomyopathy. Evaluation of innovative treatments for specific cardiac pathologies.

  • Cardiomyopathy management
  • Rare cardiac diseases
  • Targeted therapeutic approaches

Focused studies on improving survival rates and quality of life in specialized cardiac conditions.

04 Stroke Management

Clinical trials examining treatments for acute ischemic stroke and high-risk transient ischemic attacks. Studies evaluating new therapeutic options for stroke prevention and management.

  • Post-stroke care
  • TIA management
  • Stroke prevention strategies

Development of advanced treatments for better stroke outcomes.

05 Oncology Research

Studies investigating the role of acetylsalicylic acid in improving survival rates for colon cancer patients. Research focused on preventing cancer recurrence after surgical intervention.

  • Colon cancer treatment
  • Post-surgical care
  • Cancer recurrence prevention

Innovative approaches in cancer survival improvement strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.